BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang N, Tsuruoka S, Yamamoto H, Enosawa S, Omasa T, Sata N, Matsumura T, Nagai H, Fujimura A. The Bioreactor With CYP3A4- and Glutamine Synthetase-Introduced HepG2 Cells: Treatment of Hepatic Failure Dog With Diazepam Overdosage. Artificial Organs 2005;29:681-4. [DOI: 10.1111/j.1525-1594.2005.29107.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
Number Citing Articles
1 Zhang X, Lu J, He B, Tang L, Liu X, Zhu D, Cao H, Wang Y, Li L. A tryptophan derivative, ITE, enhances liver cell metabolic functions in vitro. Int J Mol Med 2017;39:101-12. [PMID: 27959388 DOI: 10.3892/ijmm.2016.2825] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
2 Zhao LF, Pan XP, Li LJ. Key challenges to the development of extracorporeal bioartificial liver support systems. Hepatobiliary Pancreat Dis Int 2012;11:243-9. [PMID: 22672816 DOI: 10.1016/s1499-3872(12)60155-6] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
3 Dutta SK, Ghosh S, De S, Hoffman EP. CYP1A1 and MT1K are congener specific biomarker genes for liver diseases induced by PCBs. Environ Toxicol Pharmacol 2008;25:218-21. [PMID: 21783860 DOI: 10.1016/j.etap.2007.10.018] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
4 Araki N, Tsuruoka S, Hasegawa G, Yanagihara H, Omasa T, Enosawa S, Yamazoe Y, Fujimura A. Inhibition of CYP3A4 by 6',7'-dihydroxybergamottin in human CYP3A4 over-expressed hepG2 cells. J Pharm Pharmacol 2012;64:1715-21. [PMID: 23146034 DOI: 10.1111/j.2042-7158.2012.01562.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
5 van Wenum M, Chamuleau RA, van Gulik TM, Siliakus A, Seppen J, Hoekstra R. Bioartificial livers in vitro and in vivo : tailoring biocomponents to the expanding variety of applications. Expert Opinion on Biological Therapy 2014;14:1745-60. [DOI: 10.1517/14712598.2014.950651] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 3.7] [Reference Citation Analysis]
6 Araki N, Tsuruoka S, Wang N, Hasegawa G, Yanagihara H, Ando H, Omasa T, Enosawa S, Nagai H, Fujimura A. Human CYP3A4-introduced HepG2 cells: In vitro screening system of new chemicals for the evaluation of CYP3A4-inhibiting activity. Xenobiotica 2008;38:1355-64. [DOI: 10.1080/00498250802468645] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
7 Nibourg GAA, Huisman MT, van der Hoeven TV, van Gulik TM, Chamuleau RAFM, Hoekstra R. Stable overexpression of Pregnane X receptor in HepG2 cells increases its potential for bioartificial liver application: PXR Overexpression in HEPG2 for a Bioartificial Liver. Liver Transpl 2010;16:1075-85. [DOI: 10.1002/lt.22110] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
8 Malchesky PS. Artificial Organs 2005: A Year in Review. Artificial Organs 2006;30:192-207. [DOI: 10.1111/j.1525-1594.2006.00206.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
9 Pan X, Li L. Advances in cell sources of hepatocytes for bioartificial liver. Hepatobiliary & Pancreatic Diseases International 2012;11:594-605. [DOI: 10.1016/s1499-3872(12)60230-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
10 Ghosh S, De S, Chen Y, Sutton DC, Ayorinde FO, Dutta SK. Polychlorinated biphenyls (PCB-153) and (PCB-77) absorption in human liver (HepG2) and kidney (HK2) cells in vitro: PCB levels and cell death. Environ Int 2010;36:893-900. [PMID: 20723988 DOI: 10.1016/j.envint.2010.06.010] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
11 Nibourg GA, Chamuleau RA, van Gulik TM, Hoekstra R. Proliferative human cell sources applied as biocomponent in bioartificial livers: a review. Expert Opinion on Biological Therapy 2012;12:905-21. [DOI: 10.1517/14712598.2012.685714] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
12 Su Y, Chen Z, Yan L, Lian F, You J, Wang X, Tang N. Optimizing combination of liver-enriched transcription factors and nuclear receptors simultaneously favors ammonia and drug metabolism in liver cells. Experimental Cell Research 2018;362:504-14. [DOI: 10.1016/j.yexcr.2017.12.015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
13 Chamuleau RAFM, Hoekstra R. End-stage liver failure: filling the treatment gap at the intensive care unit. J Artif Organs 2020;23:113-23. [PMID: 31535298 DOI: 10.1007/s10047-019-01133-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Ghosh S, De S, Dutta SK. Altered protein expressions in chronic PCB-153-induced human liver (HepG2) cells. Int J Toxicol 2007;26:203-12. [PMID: 17564901 DOI: 10.1080/10915810701352648] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
15 Hoekstra R, van Wenum M, Chamuleau R. Pivotal preclinical trial of the spheroid reservoir bioartificial liver. Journal of Hepatology 2015;63:1051-2. [DOI: 10.1016/j.jhep.2015.06.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
16 Minagawa K, Koyama T, Miyoshi H. Stimulating effects of fibroblast growth factors on hepatic function of fetal liver cells synergistically with oncostatin M in three-dimensional culture. J Biosci Bioeng 2009;107:307-11. [PMID: 19269598 DOI: 10.1016/j.jbiosc.2008.10.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]